Publication | Closed Access

A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission

Hematological MalignancyRadiation OncologyChronic Myeloid LeukemiaCell TherapyAdjuvant ImmunotherapyImmunologyHematologyMyeloid NeoplasiaAutoimmunityImmunotherapyMedicineCell TransplantationNatural Killer CellsClinical RemissionHealth Sciences